Thiamine HCl Injection, USP 200 mg/2 mL (100mg/mL), 2 mL vials, packaged in 25 (2 mL multi-dose v...
FDA Drug Recall #D-0601-2021 — Class III — May 3, 2021
Recall Summary
| Recall Number | D-0601-2021 |
| Classification | Class III — Low risk |
| Date Initiated | May 3, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Institutional LLC |
| Location | Rockford, IL |
| Product Type | Drugs |
| Quantity | 2,131 cartons |
Product Description
Thiamine HCl Injection, USP 200 mg/2 mL (100mg/mL), 2 mL vials, packaged in 25 (2 mL multi-dose vial) per carton, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103 USA; Manufactured by: Mylan Institutional, Galway, Ireland. NDC: 67457-196-02
Reason for Recall
Labeling: Incorrect or Missing Lot and/or Exp Date: Cartons with the correct lot number 200906 contain vials labeled with the incorrect lot number 200901.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot #: 200906, Exp. Date February 2022
Other Recalls from Mylan Institutional LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1575-2020 | Class I | Amiodarone Hydrochloride Injection, USP, 450 mg... | Aug 17, 2020 |
| D-1576-2020 | Class I | Tranexamic Acid Injection, USP, 1000 mg/10 mL (... | Aug 17, 2020 |
| D-1484-2020 | Class I | Daptomycin for Injection, 500 mg/vial, Single-D... | Jul 7, 2020 |
| D-1271-2020 | Class II | Aloprim (allopurinol sodium) for Injection, 500... | May 5, 2020 |
| D-1329-2015 | Class I | Cytarabine Injection 100 mg/5 mL (20 mg/mL), 5 ... | Apr 23, 2015 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.